ShapeShapeauthorShapecrossShapeShapeShapeGrouphamburgerhomeGroupmagnifyShapeShapeShapeShape

Floxabactin - a new antibiotic treatment from Dechra

Available in multiple dose strengths, Floxabactin enables veterinary professionals to treat all sizes of patient

09 July 2020, at 9:00am

Dechra Veterinary Products has launched a new antibiotic to treat urinary tract infections in dogs and upper respiratory tract infections in cats.

Floxabactin, which has the active ingredient Enrofloxacin, is indicated for use in dogs with lower UTIs including those associated with prostatitis, upper urinary tract infections caused by Escherichia coli or Proteus mirabilis in dogs, and superficial and deep pyoderma. For cats, the 15mg dose can be used with upper respiratory tract infections.

Produced in multiple tablet strengths - 15mg for cats and dogs and 50mg and 150mg just for dogs - it is available in handy blister packs for quick and easy dispensing.

Dechra Brand Manager Carol Morgan said one of the key benefits of the latest addition to Dechra’s antibiotic portfolio was its availability in multiple dose strengths, enabling veterinary professionals to treat all sizes of patient.

“Floxabactin has been developed with the responsible administration of antibiotics in mind. We would always promote only using antimicrobials when an infection has been documented and based on the results of culture and sensitivity testing, and or cytology testing, if applicable.

“Other treatment options should also be considered before the systemic use of antibiotics such as topical treatment for superficial pyoderma.”

For more information about Floxabactin and Dechra’s antibiotic range, visit the website.